K. Utsunomiya, Seigo Kakiuchi, M. Senda
Feb 8, 2020
Citations
0
Influential Citations
7
Citations
Quality indicators
Journal
Journal of Diabetes Investigation
Abstract
Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor, and is currently used to treat patients with type 2 diabetes mellitus. We designed a 3‐year study of tofogliflozin in patients with type 2 diabetes mellitus to evaluate the safety and effectiveness in routine clinical practice. The 3‐ and 12‐month interim analysis showed tofogliflozin was well‐tolerated, safe and clinically effective. Here, we report the results of the 24‐month interim analysis.